APLS
$17.21-0.76 (-4.23%)
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.
Recent News
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.
Assessing Apellis Pharmaceuticals (APLS) Valuation After Weaker Returns And EMPAVELI Label Expansion
Recent share performance and business snapshot Apellis Pharmaceuticals (APLS) has drawn fresh attention after a stretch of weaker share performance. The stock is around $18.94 and has recorded negative returns over the past month, past 3 months, year to date, and past year. The company generated about $1.00b in revenue and net income of roughly $22.39m. This performance was supported by commercial products EMPAVELI and SYFOVRE, along with a broader pipeline targeting complement driven...
Adobe downgraded, Nio upgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Top 5 Upgrades: HSBC upgraded Nio (NIO) to Buy from Hold with a price target of $6.80, up from $4.80.
Here is Why JPMorgan is Overweight on Apellis Pharma (APLS)
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 5, Anupam Rama from JPMorgan increased the price target on Apellis Pharmaceuticals Inc. (NASDAQ:APLS) from $36 to $37. The analyst reiterated his Overweight rating on the stock, which currently offers an adjusted upside potential […]
Apellis Pharmaceuticals Details SYFOVRE, EMPAVELI Growth Plans and FcRn Gene-Editing Push at TD Cowen Conf.
Apellis Pharmaceuticals (NASDAQ:APLS) executives outlined a three-part strategy for the company at TD Cowen’s 46th Annual Healthcare Conference, emphasizing a “durable and resilient” SYFOVRE franchise in geographic atrophy (GA), an expanding EMPAVELI launch in rare kidney diseases, and a pipeline th